219 results about "ALI - Acute lung injury" patented technology

The present invention refers to a peptidic or non-peptidic angiotensin-(1-7) (Ang-(1-7)) receptor agonist, preferably a Mas receptor agonist, for the prevention and / or treatment of acute lung injury, preferably acute respiratory distress syndrome.

The invention features methods of treating a subject having a lung disorder such as lung inflammation and injury, by administering antithrombin III through pulmonary delivery.

A patient is monitored for a medical condition such as acute lung injury (ALl) by operations including: (i) receiving values of a plurality of physiological parameters for the patient; (ii) computing an ALl indicator value based at least on the received values of the plurality of physiological parameters for the patient; and (iii) displaying a representation of the computed ALl indicator value on a display (14, 22). The computing operation (ii) may employ various inference algorithms trained on a training set comprising reference patients to distinguish between reference patients having ALl and reference patients not having ALl, or may employ an aggregation of two or more such inference algorithms. If patients in an ICU are monitored, the display (22) may simultaneously display a diagrammatic representation of each patient including an identification of the patient and a representation of the ALl indicator value for the patient.

The invention discloses a composition containing radix Codonopsis pilosulae and radix Astragali and hedysari, The main component is made from radix Codonopsis pilosulae and radix Astragali and hedyyari in certain rate. The invention also discloses the method of producing it and the use for producing immune system-regulated agent and these medicaments for treatment of ischemic heart disease or acute pulmonary damage.

The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

A composition comprising a water-soluble and stable complex formed by an alkyl ether derivative of gamma-cyclodextrin and curcumin and optionally comprising non-complexed cyclodextrin, the molar ratio of curcumin to cyclodextrin being between 1:1 and 1:6, and a method of manufacturing such a composition. The water-soluble and stable complex of curcumin is useful in therapy, e.g. for treatment of cancer, leukemia, myocardial infarction, stroke, sepsis, acute lung injury, acute liver failure, acute tubular necrosis, acute pancreatitis, radiation injury and other life-threatening conditions in a human or animal subject, as well as for preserving human or animal organs, tissues or cells at a hypothermic temperature.

The present invention relates to the use of modified factor VI[ for manufacture of medicaments for treatment of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) in humans.

The invention relates to preparation and a purification production process of mesenchymal stem cells (MSCs) derived exosomes, and application of the exosomes as a non-cell therapy in the treatment of acute lung injury. The MSCs deriving the exosomes belong to the wall adhesion type of stem cells, and the preparation and purification process have the characteristics that (1) parathyroid hormone is added specially for the preparation of MSCs condition medium, and (2) discontinuous Ficoll density gradient method and immunomagnetic beads separation and purification method are combined for separation and purification so as to obtain the exosomes. Rat acute lung injury (ALI) model experiments confirm that the exosomes can be used for treatment of ALI, so as to lay the foundation for the realization of non-stem cell therapies to substitute stem cells therapies.

The invention provides a stem cell derived exosome preparation for preventing and treating lung jury. Lung injury includes acute lung injury, radiation lung injury, pulmonary fibrosis, silicosis and the like. The preparation is prepared from stem cell derived exosomes, and after a trachea cannula or intravenous injection reaches injured lungs, recovery of injured tissue structure and function is promoted; the preparation is an acellular preparation, so that the risk of cell mutation is lowered; the stem cell derived exosomes repair and maintain the function in lung tissue; treatment effect oflung injury and fibrosis is enhanced.

Evidence is presented that inflammation and injury involves activation of xanthine oxidoreductase (XOR) in the newly recruited mononuclear phagocytes (MNP). XOR has been shown to be increased predominantly in the MNP that increase rapidly in the lungs of rats that develop acute lung injury (ALI) following intratracheal cytokine insufflation. XOR was recovered from the MNP largely converted to its oxygen radical generating, reversible O-form, and alveolar MNP exhibited increased oxidative stress as evidenced by increased nitrotyrosine staining. Cytokine insufflation also increased alveolar cell apoptosis. A functional role for XOR in cytokine induced inflammation was demonstrated. Tungsten and allopurinol decreased MNP XOR induction, nitrotyrosine staining, inflammatory cell infiltration, and alveolar cell apoptosis. Transfer of control or allopurinol treated MNP into rat lungs and confirmed a specific role for MNP XOR in promoting lung inflammation. These data indicate that XOR can contribute to lung inflammation by its expression and conversion in a highly mobile inflammatory cell population.

The invention discloses application of oridonin powder aerosol in treatment of acute lung injury. The oridonin powder aerosol is prepared by an oridonin nano-drug delivery system, wherein the dosage form of the nano-drug delivery system is selected from lipidosome, nanoparticles, nanosuspension, nanoemulsion and micro-emulsion. The medicines in the oridonin powder aerosol are stable, easily enter the deep parts of lung tissues, are positioned in a targeted mode and are convenient to carry and use, and the treatment of acute lung injury is promoted. The oridonin powder aerosol is used for treating the acute lung injury caused by infection, shock, smoking, trauma, toxin poisoning, inhalation of irritant gases, radiation, high oxygen and low oxygen, wherein the inhaled irritant gases comprise phosgene, diphosgene, triphosgene, chlorine, nitric oxides, formaldehyde, dimethyl sulfate, hydrogen chloride, hydrogen bromide, hydrogen fluoride, ammonia, ozone and sulfur dioxide.

The invention provides a medicament for treating infectious diseases, a preparation method and the application thereof. The medicament is prepared from scutellaria baicalensis, jasmine, erigeron breviscapus and cholic acid, and has the following effects: by aiming at the central link--inflammatory reaction of an infectious disease, removing harmful substances such as inflammatory mediators, free radicals and the like, and improving the local microcirculation state, thereby alleviating the pathological damages caused by inflammations; meanwhile, the medicament has the function of regulating the overall internal environment, and can effectively treat lower respiratory tract infection and acute lung injury induced by infection; and the effective substances and functional mechanism of the medicament are relatively clear.

The invention discloses an application of a dry curcumin nano-powder inhalant in treatment of acute lung injury. The dry curcumin nano-powder inhalant is prepared from a curcumin nanometer administration system. The dosage form of the curcumin nanometer administration system is selected from a liposome, a nano-particle, a nano-emulsion and a micro-emulsion. The curcumin nanometer administration system with or without auxiliary materials is dried to form a solid powder, and the solid powder is mixed with a carrier to obtain the dry curcumin nano-powder inhalant. The dry curcumin nano-powder inhalant has the advantages of stable drugs, easy entrance of the deep portion of lung tissues, targeted positioning, carrying and use convenience, and benefiting for the treatment of the acute lung injury. The dry curcumin nano-powder inhalant is used for treating acute lung injury caused by infection, shock, smoking, wounds, poisoning, irritating gas inhalation, radiation, high oxygen and low oxygen. Irritating gases comprise phosgene, diphosgene, triphosgene, chlorine, nitrogen oxide, formaldehyde, dimethyl sulfate, hydrogen chloride, hydrogen bromide, hydrogen fluoride, ammonia, ozone and sulfur dioxide.

The invention discloses application of a compound to preparation of a medicament for treating the acute lung injury. The compound disclosed by the invention can effectively reduce a death rate causedby the acute lung injury and recover the normal lung function, and a treatment effect of the compound is equivalent to that of dexamethasone acetate; and in addition, the compound can be orally taken,is more convenient to use and has important medical prospect and economic value.

The invention discloses an application of eupatorium sesquiterpene components in preparing a drug for resisting acute lung injury. Eupatorium sesquiterpene components are made into a veterinary drug. A technical solution provided by the invention comprises the steps of making the eupatorium sesquiterpene componentsinto a veterinary drug; inducing acute lung injury in mice by using lipopolysaccharide (LPS) in a manner of in-vivo dosing to the mice; then determining a lung wet / dry ratio of the mice with the acute lung injury, the content of nitric oxide (NO) and protein in a bronchoalveolar lavage fluid (BALF); detecting activities of myeloperoxidase (MPO) and superoxide dismutase (SOD) in lung tissue homogenate, the content of tumor necrosis factor-alpha (TN-alpha), interleukin-6 (IL-6) and interleukin-1[beta] (IL-1[beta]) in the BALF and the content of complement C3 and C3c in blood serum; and observing pathological changes of lung tissues of the mice after H&E staining. Results show that eupatorium sesquiterpene components of eupalinolide F, eupalinolide G, eupalinolide H, eupalinolide I and eupalinolide K have activity for resisting the acute lung injury.

Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and / or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.

The invention discloses separation and preparation of a euphorbia factor L2 and a novel application of the euphorbia factor L2 to treatment of acute lung injury. The euphorbia factor L2 is a diterpeneester compound extracted and separated from semen euphorbiae lathyridis serving as a traditional Chinese medicinal material and displays good treatment effects on a lipopolysaccharide induced acute lung injury mouse model, and the euphorbia factor L2 has exact functions of resisting inflammatory diseases such as the acute lung injury and can be combined with auxiliary materials to prepare a medicine for resisting the inflammatory diseases such as the acute lung injury of a respiratory system or combined with other medicines for treating the acute lung injury in application.

The invention discloses an application of a chlorogenic acid nano powder inhalation in a medicine for treating acute lung injury. The chlorogenic acid nano powder inhalation is prepared with a chlorogenic acid nano medicine delivery system selected from the dosage forms of lipidosomes, nano-particles, nano-emulsions and micro-emulsions with or without addition of an auxiliary material. The medicine delivery system is dried into solid powder and is then mixed with a carrier to prepare the chlorogenic acid nano powder inhalation. The nano powder inhalation is stable, is easy to enter the deep parts of lung tissue, allows targeted positioning, is convenient to carry and use and has advantages on treatment of the acute lung injury. The chlorogenic acid nano powder inhalation is used for treating acute lung injuries caused by infection, shock, smoking, wound, poisoning, inhalation of simulative gas, irradiation, high-oxygen and low-oxygen atmospheres and the like. The simulative gas herein comprises phosgene, diphosgene, triphosgene, chlorine, nitrogen oxides, formaldehyde, dimethyl sulfate, hydrogen chloride, hydrogen bromide, hydrogen fluoride, ammonia, ozone and sulfur dioxide.

The invention discloses a carbonic oxide inhalator which comprises a control part, a measuring circuit part and a CO-air mixing device. The CO-air mixing device is provided with a CO inlet, an air inlet and a mixed gas outlet. The control part comprises a computer and a displayer. The measuring circuit part comprises a pressure sensor, a current amplifier, a filter and an A / D convertor, wherein the pressure sensor measures the gas pressure of input CO gas, air and mixed gas, current amplification and filtering are conducted on the gas pressure through the current amplifier and the filter respectively, then the gas pressure is converted into a digital signal through the A / D convertor and is input into the computer, and the computer analyzes data of the measuring circuit part and outputs a control command. The carbonic oxide inhalator is used for treating diseases such as pulmonary arterial hypertension, ARDS, respiratory failure caused by acute lung injury, hypoxic ischemic brain damage and shock.

The invention discloses a cefaclor medicinal composition and an acute lung injury protection effect thereof. The cefaclor medicinal composition contains cefaclor and a natural product compound (I) having a novel structure and separated from dry rhizome of Grassleaf Sweelflag Rhizome, and cefaclor and the natural product have lung injury prevention and treatment effects in the individual action process; and cefaclor and the natural product have further improved lung injury prevention and treatment effects when being combined, so cefaclor and the natural product can be used to develop lung injury prevention and treatment medicines. Compared with medicines in the prior art, the medicinal composition has protruding characteristics and substantial progresses.

The invention relates to the technical field of medicine, in particular to an application of a TIPE2 (tumor necrosis factor-alpha induced protein 8 like-2) agonist in immunoregulation drugs for treating endotoxin sepsis complicated with acute lung injury. A model of the endotoxin sepsis complicated with acute lung injury is established, the protection effect testing of the TIPE2 agonist on the sepsis complicated with acute lung injury is performed, and the regulating function of a TIPE2 agonist on the sepsis immune system is achieved, so that the organism damage caused by excessive activation of the immune system can be prevented. According to the invention, exact laboratory data is provided for treatment of sepsis complicated with acute lung injury by the aid of the TIPE2 agonist, and corresponding scientific basis is further provided for an immunomodulatory therapeutic mechanism with the application of the TIPE2 agonist clinically.

The invention provides Pyxinol esterification derivatives having anti-inflammatory activity and a preparing method and application thereof, particularly relates to Pyxinol esterification derivatives,a preparing method thereof and anti-inflammatory applications of the derivatives, and belongs to the technical field of novel compound invention, preparation and application. The applications of the derivatives shown as a general formula (I) in preparation of anti-inflammatory medicines or medicine compositions particularly relate to applications in preparation of medicines or medicine compositions for treating and preventing acute lung injuries, septicopyemia and other related diseases. The compounds provided can adopt oral administration, injection and other clinical administration manners.The clinical dosage of the compounds is 0.01-1000 mg / day, and can be increased or decreased according to the state of an illness or dosage forms.

The present invention discloses a use of cholesterol-modified HuR interference siRNA in preparation of drugs for treating acute lung injury caused by sepsis. According to the present invention, the related HuR interference siRNA is an artificially-synthesized and cholesterol-modified small nucleic acid drug; with intravenous administration, results show that the HuR siRNA can be richly distributed in lung tissue, enter lung cells, inhibit a plurality of 3'-UTR of mRNA of inflammatory factors having HuR binding sites, and promote TNFalpha RNA degradation so as to inhibit acute lung injury induced by bacterial lipopolysaccharide (LPS), wherein TNFalpha expression can be inhibited; and the small nucleic acid drug provides significant release effects for lung inflammation, is applicable for intravenous administration, inhalation administration or intratracheal administration, and is the small nucleic acid drug having application values and prospects and provided for treating acute lung injury under the premise of lack of effective and related acute lung injury treatment nucleic acid drugs in the prior art.

The invention belongs to the field of traditional Chinese medicines and particularly relates to an application of traditional Chinese medicine composition and a preparation thereof in preparation of adrug for treating ALI (acute lung injury). The traditional Chinese medicine composition is prepared from raw materials such as rhizoma paridis, radix scutellariae, thunberg fritillary bulb, common dayflower herbs, rhizoma anemarrhenae, gypsum, dried tangerine or orange peel, fructus aurantii, fructus xanthii, bitter almond kernels, radix platycodonis, cablin potchouli herbs, folium perillae and prepared liquorice roots. Study results show that the traditional Chinese medicine composition can reduce the water content and the permeability index of the lung of a model rat with ALI and reduce thelevel of cell inflammatory factors, improve change of ALI lung histopathology, has a remarkable treatment effect on ALI and is suitable for clinical popularization and application.

The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R1, R2, R3, R4, R5, X1, and X2 are as defined herein, and pharmaceutical compositions thereof. Also provided are methods of use and treatment. Such compounds have been found useful in the treatment of malaria infection. Such compounds may also be useful in the treatment of inflammatory conditions, such as acute lung injury and acute respiratory distress syndrome, which optionally may be associated with a malaria infection.

The invention discloses a method for establishing an acute lung injury animal model, and relates to the technical field of bioengineering. The method for establishing the acute lung injury animal model comprises the following steps: anesthetizing and fixing an experimental animal; inducing acute lung injury of the experimental animal by combining hydrochloric acid with mechanical ventilation; andevaluating the degree of acute lung injury. According to the method, acute pathological injury of the lung of the experimental animal is induced by combining hydrochloric acid with mechanical ventilation, the animal model of acute lung injury can be constructed, and the animal model shows typical characteristics of acute lung injury, such as dyspnea, lung tissue edema and lung tissue fibrosis. Themodel can be used for basic research in the related field of acute lung injury, and lays an experimental animal foundation for exploring the pathogenesis of acute lung injury.

A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The invention relates to a method for preparing a NO2 adsorption reducing material, which belongs to a method for preparing a gas purifying material and solves the problems of higher micropore proportion, lower mesopore proportion and low NO2 selective adsorption of active carbon prepared by the traditional preparation method. The method sequentially comprises the steps of carbonization, activation and modification processing. The invention can obtain active carbon with high specific surface area, the specific surface areas of a mesopore and a micropore are obviously improved, and the specific surface area of the mesopore is improved to more than 40 percent; and the prepared adsorption reducing material can be used for purifying an inspiratory nitric oxide gas treating relevant diseases, such as acute lung injury and persistent pulmonary hypertension of the new born, high altitude pulmonary edema, lung transplantation reperfusion injury, acute respiratory failure, pulmonary hypertension, and the like, and also be used for separating a NO and NO2 mixed gas to produce a NO gas with high purity.

The invention belongs to the technical field of medicines for preventing and treating acute lung injury, and discloses application of a fritillaria heterosteroid alkaloid monomer, namely application of the fritillaria heterosteroid alkaloid monomer in preparation of medicines for treating, relieving or preventing lung injury. Lung injury is acute lung injury induced by LPS. The lung injury can also be caused by influenza virus infection, bacterial infection and / or fungal infection. The fritillaria heterosteroid alkaloid monomer comprises dehydroobberidine and peimisine. The invention further discloses a preparation method of the fritillaria heterosteroid. According to the invention, corresponding representative compounds, namely dehydroobberidine and peimisine, are selected for an activity experiment for preventing and treating the acute lung injury, and the two natural small-molecule alkaloid monomers, namely dehydroobberidine and peimisine, are determined to have good activity for preventing and treating the acute lung injury, and can obviously relieve lung inflammation and pulmonary edema conditions; the new application disease range of fritillaria plants is widened, and a reliable direction and basis are provided for development of safe and effective new drugs for acute lung injury.